• 
• 
• 
• 

FDA News and Drug Updates

FDA Approves Polivy in Combination with Bendamustine plus Rituximab for Patients with Relapsed, Refractory DLBCL

Xpovio plus Dexamethasone Combination Receives Accelerated Approval for the Treatment of Patients with Relapsed or Refractory MM

Keytruda Approved for Patients with Previously Treated Metastatic Small-Cell Lung Cancer

Supportive Care

What an Aging Population Means for Cancer Treatment

Saima Iqbal, Ishmam Khan

Supportive Care Updates from ASCO 2017 Highlighted at New Orleans Summer Cancer Meeting

Meg Barbor, MPH

Helping Adolescents and Young Adults Confront Mortality

Meg Barbor, MPH

View All Supportive Care Articles

Lung Cancer

Osimertinib plus Savolitinib Promising for Non–Small-Cell Lung Cancer with MET-Driven Resistance

Phoebe Starr

High Tumor Mutation Burden Predictive Biomarker for Survival in Metastatic Non–Small-Cell Lung Cancer

Phoebe Starr

Lorbrena (Lorlatinib) Approved for the Treatment of Metastatic Non–Small-Cell Lung Cancer with ALK Mutation

Loretta Fala, Medical Writer

View All Lung Cancer Articles

Conference Correspondent

Sexual Dysfunction After Cancer: Why Aren’t We Talking About It?

The Importance of Compassion: Perspective From a Lifelong Patient

Using a Team Approach to Tackle Opioid Abuse in Patients with Cancer

Addressing the Second Victim Phenomenon

Palliative Care Use Dismal Among Patients with Hematologic Malignancies

View All Conference Correspondent Articles

Most Popular Articles

Preserving Sexual Function in Women After Cancer Treatment

Meg Barbor, MPH

TON - August 2019, Vol 12, No 4 - ONS

Fox Chase Cancer Center: Making a Difference in Patients' Lives

TON - August 2019, Vol 12, No 4 - Cancer Center Profile

FDA Approves Polivy in Combination with Bendamustine plus Rituximab for Patients with Relapsed, Refractory DLBCL

TON - August 2019, Vol 12, No 4 - FDA Approvals

Xpovio plus Dexamethasone Combination Receives Accelerated Approval for the Treatment of Patients with Relapsed or Refractory MM

TON - August 2019, Vol 12, No 4 - FDA Approvals